DSM has delivered a Q3 increase in EBITDA earnings of 27% across all its divisions despite “headwinds” like the ongoing economic flatline in Europe and elsewhere, challenging currency movements and rising ingredient costs.
DSM’s nutrition unit performed well with the Martek acquisition helping 13% sales growth, but the polymers and pharma faired worse, leaving the company with 3% overall growth, but a dipped EBITDA of €306m for the quarter.
DSM’s human nutrition corporate scientist, Wim Saris, spoke with Shane Starling recently after chairing a weight management and satiety conference in Amsterdam. He voiced his concern about spiralling health claim costs muzzling innovation.
DSM Food Specialities has developed a new mould and yeast inhibitor
for meat products, said to ensure an even coating of natamycin on
products like sausages and give stronger protection against health
DSM Food Specialities and starch specialist Avebe have entered into
a strategic partnership to develop innovative ingredients to
enhance creaminess in food products, particularly in the dairy and